英夫利昔单抗治疗川崎病的进展

Progress in treatment of Kawasaki disease with Infliximab

摘要:

川崎病是一种全身血管炎症病变引发的儿童急性发热出疹性疾病，近年来发病率逐年递增，特别是难治性川崎病。随着生物医学及药学的飞速发展，临床上逐渐开始用生物制剂替代传统治疗，并已取得一定效果。该文针对英夫利昔单抗在川崎病，特别是难治性川崎病中的应用进展进行综述。

Abstract:

Kawasaki disease is manifested with acute fever and rash disease caused by systemic vascular inflammation. In recent years, morbidity has increased, especially refractory Kawasaki disease. With the rapid development of biomedicine and pharmacy, biological agents have gradually begun to replace traditional treatment with satisfying efficacy. This article reviews the progress in the application of Infliximab in Kawasaki disease, especially in refractory Kawasaki disease.